Condition: Colorectal Cancer · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
This description comes directly from the study's public registry record.
binbin Min · 0512-69566088 · bingo.min@innoventbio.com
Always discuss trial participation with your own doctor first.
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Wuhan, China | — |
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07722494